| Nemaura Medical (NASDAQ: NMRD) Receives CE Mark Approval |
| |
|
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, announced it has received CE Mark approval for SugarBEAT®. With this approval, Nemaura is permitted to commence sales of SugarBEAT® throughout the European Union.
Key Quote: "We are very pleased to report CE Mark approval in Europe for SugarBEAT®, which is the world’s first non-invasive, needle-free, continuous glucose monitor (CGM). Importantly, as a daily disposable adhesive skin-patch that sits on the surface of the skin, SugarBEAT® is painless, and versatile in terms of wear time. Given these benefits, we look forward to aggressively entering both the multi-billion-dollar diabetic (insulin and non-insulin dependent) and pre-diabetic markets. In addition, we plan to target the wearable health tech market for health-conscious consumers, which is experiencing explosive growth. Due to the non-invasive nature of the sensor patch and connection to a rechargeable transmitter, SugarBEAT® will allow users the freedom to decide when and for how long to wear the patch. Moreover, we have a unique competitive advantage, which we believe will make SugarBEAT® the lowest priced CGM device in the industry. SugarBEAT® is protected by a solid IP portfolio with over 30 issued and pending patents across multiple patent families." Dr. Faz Chowdhury, CEO
What's Next: While the company begins to ramp sales in the EU, it is also moving forward in its FDA approval process. According to the last update from management, Nemaura remains on track to apply for FDA approval in mid-2019.
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
|
|
| |
|
| Wize Pharma (OTCQB: WIZP) Issues Letter to Shareholders |
| |
|
Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, issued a Letter to Shareholders:
“We are very pleased to report on our recent corporate and clinical accomplishments, as well as our plans for significant value-driving events in the upcoming quarters. The $3.7 billion global market for the treatment of ophthalmic disorders is primed for new technologies that can potentially optimize treatment and recovery for the benefit of patients and ameliorate the economics of treatment for providers and payers. One recent industry deal which underscores this point is Novartis' offer to acquire Takeda's eye drug assets for up to $5.3 billion. Data from the Phase II clinical study of LO2A for the symptomatic treatment of DES in patients with moderate to severe conjunctivochalasis (CCh) achieved its primary efficacy endpoint. Evidence of efficacy in multiple clinical measures was revealed based on a full statistical analysis of the study results. Statistical significance was witnessed using a mixed model analysis with multiple observations.”
To view the full press release, visit: http://yhoo.it/2QxMeVd
The Backstory: Wize Pharma, Inc. (OTCQB: WIZP) is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including DES. Wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including CCh and Sjögren's syndrome (Sjögren's).
LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCH and Sjögren's and in the Netherlands for the treatment of DES and Sjögren's. Wize's strategy involves engaging local or multinational distributors to handle the distribution of LO2A. Wize has finished a Phase II trial of LO2A for patients with CCH and is currently conducting a Phase IV study for LO2A for DES in patients with Sjögren's.
|
|
| |
|
| Piedmont Lithium (NASDAQ: PLL) to Hold Webinar Wed., May 29, 1 pm ET |
| |
|
Piedmont Lithium Ltd (NASDAQ: PLL), a company holding a 100% interest in the Piedmont Lithium Project in North Carolina, the only conventional lithium project in the United States, will host an investor webinar and live Q and A session Wednesday, May 29, 2019 at 1 pm Eastern/10 am Pacific.
To view the webinar, which is free of charge and requires no registration, please visit www.redchip.com/events/41/piedmont-lithium-webinar. For questions about PLL, please call RedChip specialist Craig Brelsford at (407) 571-0902.
The webinar will feature a presentation by Keith D. Phillips, President and CEO of PLL. Mr. Phillips will discuss the competitive positioning of PLL, the Company's growth opportunities, value proposition, and more. Following the presentation, Mr. Phillips will take questions from attendees.
About Piedmont Lithium Ltd (NASDAQ: PLL)
Market cap: $80 million
Holds 100% interest in Piedmont Lithium Project in world-class Carolina Tin-Spodumene Belt, one of the largest lithium provinces in the world, 25 miles west of Charlotte
The Piedmont Lithium Project enjoys a prime location and exceptional economics. Compared to projects in Australia and Canada, North Carolina offers a lower-cost, lower-tax operating environment. In addition, the Project offers easy access to major high-tech population centers and downstream lithium-processing facilities
Lithium is on the U.S. government’s critical minerals list, giving the Project significant strategic value as the only conventional U.S. lithium development project
Benchmarking shows deep undervaluation vs. peers. PLL has an EV/steady-state EBITDA of ~0.3x vs. peers at 1.0x-2.5x
Key Quote: "As the only conventional lithium project in the USA, we have attracted considerable strategic interest and have engaged in initial conversations with parties in the lithium, mining, chemicals, battery, automotive, and private equity sectors." Keith D. Phillips, President and CEO
View Investor Deck: www.slideshare.net/RedChip/piedmont-lithium-ltd-corporate-presentation-may-2019
More information: piedmontlithium.com/, www.pllinfo.com/
Disclosure
Piedmont Lithium (PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services
|
|
| |
|
| Small Caps Are Flashing a Buy Signal |
| |
|
John Pesinos, managing editor of several popular investment newsletters, believes small caps can help you mitigate risk and maximize growth in the current climate, where some believe the easy money of this bull market is behind us.
In his in-depth analysis, he makes the case for why you need to calibrate your portfolio to the “challenges ahead” and how small-cap stocks can play a key role.
Read the full analysis here: www.investingdaily.com/48484/small-caps-are-flashing-a-buy-signal/
|
|
| |
|
| Genetic Technologies (NASDAQ: GENE) Completes Offering of Approx. $1.2M of American Depositary Shares |
| |
|
Genetic Technologies (NASDAQ: GENE), a diversified molecular diagnostics company, completed an offering of 1.47M American Depositary Shares (ADSs) at a price of $0.80 per ADS. The offering generated an estimated $1.2 million in gross proceeds, before deducting customary offering expenses.
Why It Matters: The offering provides a fresh injection of capital to fund GENE’s expansion into China and the development of polygenic risk tests with TGen in the U.S. as well as other ongoing R&D work.
The Backstory: GENE offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products “GeneType for Breast Cancer” (non-hereditary breast cancer) and “GeneType for Colorectal Cancer” are clinically validated risk assessment tests and are first in class. The company is developing a pipeline of risk assessment products.
Disclosure
Genetic Technologies (NASDAQ: GENE) is a client of RedChip Companies, Inc. GENE agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.
|
|
| |
|
| MYnd Analytics (NASDAQ: MYND) Announces $2.8 Million Registered Direct Offering |
| |
|
MYnd Analytics (NASDAQ: MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, announced that certain investors have agreed to purchase approximately $2.8 million of the Company’s common stock in a registered direct offering.
The Company entered into a securities purchase agreement with the investors pursuant to which the Company agreed to sell 2,776,491 shares of its common stock at a per share price of $1.02. The closing of the registered direct offering is expected to take place on or about May 28, 2019, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds for general corporate purpose.
The Backstory: MYnd Analytics (NASDAQ: MYND), with its wholly owned subsidiary Arcadian Telepsychiatry Services LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues. The MYnd Psychiatric EEG Evaluation Registry (PEER) is a predictive analytics decision support tool that helps physicians reduce trial and error treatment for behavioral health conditions. PEER provides the physician a personalized care plan with recommended treatment options based on a patient’s unique brain markers, reducing treatment time and treatment costs. Arcadian Telepsychiatry Services LLC provides a suite of complementary telemedicine services that can be combined with PEER, including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. MYnd’s customers include major health plans, health systems, and community-based organizations. To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.
Disclosure
MYnd Analytics, Inc. (NASDAQ: MYND) is a client of RedChip Companies, Inc. MYND agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services.
|
|
| |
|
| Immuron (NASDAQ: IMRN): Dr. Hailey Weerts of Walter Reed Army Institute of Research (WRAIR) discusses Shigella, Travelan, and Immuron Technology Platform |
| |
|
Dr. Weerts is an immunologist on a research team involved in the development and characterization of vaccines against Shigella. The team is currently engaged in the investigation of immune responses to Shigella vaccines in pre-clinical studies and human clinical trials.
Listen to the interview: http://bit.ly/2W2eQat
The interview with Dr. Weerts will focus on her team’s research at Walter Reed Army Institute of Research, also know as WRAIR, pronounced RARE, as well as the nature of the bacteria Shigella, and their vast impact, plus about the efficacy of Travelan, and Immuron, maker of Travelan.
Why It Matters: Travelan is approved by regulatory agencies and it has passed rigorous U.S. Army tests of efficacy and treatment value.
The Backstory: Immuron Limited (NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron’s technology platform utilizes highly specific vaccines for the generation of hyperimmune antibody-rich bovine colostrum, providing a means of antimicrobial therapy without the drawbacks of antibiotics to treat gut-mediated diseases. The Company currently markets Travelan®, which is a listed medicine on the Australian Register for Therapeutic Goods, in Australia to reduce the risk of travelers’ diarrhea. In Canada, Travelan® is a licensed natural health product, and is indicated to reduce the risk of travelers’ diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| ChineseInvestors.com Inc. (OTCQB: CIIX) Subsidiary Becomes First Chinese Company to Sell CBD Products in the US |
| |
|
ChineseInvestors.com (OTCQB: CIIX), through its wholly owned subsidiary ChineseHempOil.com Inc., doing business as Chinese Wellness Center (“CWC”), recently launched a Glendale, California, mall pop-up kiosk, becoming the first Chinese company to sell CBD products in the United States.
Why It Matters: CIIX generated record revenue of $1.4M in 3QFY19, an 81% Increase YoY. Hemp and CBD sales revenues for 3QFY19 were $1.06M, a 579% increase from $0.18M in 3QFY18
The Backstory: ChineseInvestors.com, Inc. (OTCQB: CIIX), founded in 1999, offers a proprietary financial news media and content platform providing information to the Chinese-speaking community, in China, the United States, and Canada and around the world. ChineseInvestors.com, Inc. started laying the groundwork to capitalize on the growing demand for industrial hemp-based cannabidiol (CBD) nutrition and cosmetic products. By the end of 2016, the Company had begun implementing its plans for a new website for the online distribution of industrial hemp-based CBD products for the booming global cannabis industry. While cannabis use in China is illegal, hemp-based CBD can be legally added to cosmetics, thus opening a potential market of nearly 2 billion people to the Company.
Disclosure
ChineseInvestors.com, Inc. (OTCQB: CIIX) is a client of RedChip Companies. CIIX pays RedChip a monthly cash fee for twelve (12) months of investor awareness services
|
|
| |
|
| Emerald Health Therapeutics (OTCQX: EMHTF) to Lead International Affairs Council on CBD and Hemp’s Dialog with FDA on CBD Product Policy |
| |
|
Emerald Health Therapeutics (OTCQX: EMHTF) has been appointed by the American Trade Association for Cannabis and Hemp (ATACH) to lead its International Affairs Council on CBD and Hemp in ATACH’s engagement with the US Food & Drug Administration (FDA) regarding policy pertaining to CBD-containing products and associated cross-border trade.
Why It Matters: The FDA is slated to begin public consultation on May 31 to discuss potential pathways for CBD products to come to market in the US.
Key Quote: “We look forward to leveraging Emerald’s knowledge and experience as we participate in the FDA process on how to best navigate and implement a potentially-new regime for products containing cannabinoids in the United States.” - Michael Bronstein, President of ATACH
The Backstory: Emerald produces and sells its SYNC 25 CBD oil in the adult-use market and other high-CBD products in the medical market in Canada and has sourced hemp to produce allowable oils in the current Canadian legal framework. It is also employing advanced formulation and delivery technology with the goal to offer customers new product choices in conjunction with new Canadian legislation that is expected to allow a broader set of ingestible and topical products in the fall of 2019 and beyond.
|
|
| |
|
| Smith-Midland (OTCQX: SMID) Reported Revenue of $10.2 million in 1Q19, Increase of 12% YoY |
| |
|
Smith-Midland Corporation (OTCQX: SMID) develops, manufactures, licenses, rents, and sells a broad array of precast concrete products for use primarily in the construction, transportation and utilities industries, announced results for the quarter ended March 31, 2019.
First Quarter 2019 Highlights
• Revenues of $10.2 million
• Increase of $1.1 million, or 12%, over the first quarter 2018
• Gross Margin of $2.2 million, or 21.8%
• Net Income of $0.3 million
• Increase of $0.7 million over the first quarter 2018
• EPS $0.06
• Increase of $0.14 per share over the first quarter 2018
• Current backlog of $31.2 million
Key Quote: “I am pleased to announce positive earnings for the first quarter 2019 of $0.06 per share, an increase of $0.14 per share over the first quarter 2018. The increase in sales of our proprietary products including SlenderWall and Easi-Set buildings, combined with the reduction of operating expenses, helped drive the improvement to the bottom-line earnings for the first quarter 2019 over the prior year.” Ashley Smith, CEO
The Backstory: Smith-Midland develops, manufactures, licenses, rents, and sells a broad array of precast concrete products for use primarily in the construction, transportation and utilities industries.
|
|
| |
|
| |
| Quote of the Week |
| |
"Work hard, be a long-term thinker, develop tenacity and remember nothing happens without taking calculated risks."
- Phil Sassower, Chairman Phoenix Group |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
| | |
